The aim of this study is to summarize the potential molecular docking interactionsof currently approved TKIs for HER2+ breast cancer, and in non-small cell lung cancer supporting their use in key clinical trials, and in current clinical practice. This evidence concerns the gene ERBB2 and breast carcinoma.